Yang M, Chai X, Ye D, Zhao A, et al. Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin immunotherapy. J Med Econ 2026;29:672-687.
PMID: 41780023